Lung Cancer News and Research

Latest Lung Cancer News and Research

Stimuvax clinical program resumed in patients with NSCLC

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that they are resuming their Stimuvax (BLP25 liposome vaccine) clinical program in patients with non-small cell lung cancer which includes the Phase III studies, START and INSPIRE. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees.

17 Jun 2010

Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC

Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome vaccine) clinical program in patients with non-small cell lung cancer (NSCLC) which includes the Phase III studies, STARTa and INSPIREb. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees.

17 Jun 2010

LCA commends Senator John Kerry for backing Lung Cancer Mortality Reduction Act

Today, Lung Cancer Alliance commended Senator John Kerry (D-MA) for backing the Lung Cancer Mortality Reduction Act, S.332. This is the first ever authorizing legislation that establishes a multi-agency, comprehensive program targeted at lung cancer.

17 Jun 2010

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).

16 Jun 2010

Report reveals increase in patients influence on success, failure of new drugs

Patients are emerging as an increasingly strong group when it comes to influencing the success and failure of new drugs - according to a newly published New Health Report commissioned by Quintiles to gauge the opinions of biopharma executives, managed care executives and patients, and to track progress in the New Health.

16 Jun 2010

UNC researchers study why surgery happens less often in blacks with lung cancer

A new study led by UNC researchers that looks at newly diagnosed lung cancer patients and follows them from diagnosis forward is one of the first to give reasons why patients don't go to lung surgery and why surgery happens less often in blacks.

16 Jun 2010

Research investigates surgical outcomes of patients with NSCLC

Research published in the June edition of the Journal of Thoracic Oncology sought to investigate the time trends of surgical outcomes of patients with non-small cell lung cancer between 1979 and 2008. The incidence of lung cancer continues to rise; therefore, countermeasures to decrease death rates have become an important public health issue.

16 Jun 2010

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer. Results will provide researchers with a data needed to guide a phase 3 trial.

16 Jun 2010

ARBs may be linked with increased risk of developing cancer: US scientists

A common class of blood pressure drugs called angiotensin-receptor blockers may be linked with a slightly increased risk of developing cancer, US scientists have found.

16 Jun 2010

High vitamin B levels in blood reduce lung cancer risk: Study

Regular intake of Vitamin B complex can reduce the risk of getting lung cancer, researchers have found. The research paper in the Journal of the American Medical Association however emphasized that quitting smoking was the best method to reduce the risk of lung cancer. It is too early to say that vitamin supplements can actually prevent lung cancer say researchers. Lung cancer kills nearly 1.3 million people globally each year according to the World Health Organization and 10 to 15 percent of smokers develop lung cancer.

15 Jun 2010

Women who drink boiled coffee at lower risk of breast cancer

Women who drink Scandinavian boiled coffee, which chemically resembles of French press and Turkish/Greek coffee, more than four times a day run a lower risk of developing breast cancer than women who drink coffee less than once a day. This is shown by Lena Nilsson and her associates at Umeå University in an article in the journal Cancer Causes & Control.

15 Jun 2010

Researchers discover microRNA biomarkers to treat patients with SCLC

Researchers at the Translational Genomics Research Institute, the Van Andel Research Institute and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have discovered a biomarker that could help in the treatment of patients with an aggressive type of lung cancer.

15 Jun 2010

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.

14 Jun 2010

ARBs increase risk of cancer: Study

University Hospitals Case Medical Center cardiologists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs).

14 Jun 2010

Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the final analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous non-small cell lung cancer (NSCLC) showed that the study did not meet its primary endpoint of improving overall survival in the first-line setting.

14 Jun 2010

Report highlights deprivation gap caused by late diagnosis of cancer, differences in treatment choices

There could be as many as 14,000 fewer cases of cancer each year in England if everyone was as healthy as the richest 20 per cent in the country. And the difference between the classes is more marked among men than women. Among men there were 21 per cent more cases of cancer in the most deprived areas compared to the least deprived, whereas the gap among women was 11 per cent.

14 Jun 2010

Baron & Budd, P.C. attorney supports Give a Scan Program for lung cancer research

Baron & Budd, P.C. attorney John Langdoc expressed his support and enthusiasm for a new and innovative initiative by the Washington, D.C.-based Lung Cancer Alliance —called Give a Scan—to make CT Scans and clinical data donated by cancer patients easily accessible to lung cancer researchers. LCA would "de-identify" the scans and data before making the information available to researchers.

11 Jun 2010

FDA grants orphan drug designation for ICT-107

ImmunoCellular Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme. As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years.

11 Jun 2010

Family caregivers experience typical patterns of wellbeing and distress their relatives going through

Family carers need to be supported throughout the whole illness of their loved ones as they witness and share much of the experience of the dying person, according to research published on bmj.com today.

11 Jun 2010

iCAD to supply CAD technology for mammography to VA, Department of Defense Hospitals

iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced it has signed an agreement with the Defense Supply Center to provide federal healthcare facilities including Veteran's Administration (VA) and Department of Defense Hospitals with its Computer-Aided Detection (CAD) technology for mammography.

11 Jun 2010